Nabriva Therapeutics Stock Price, News & Analysis (NASDAQ:NBRV)

+0.02 (+0.91 %)
(As of 09/24/2019 06:00 AM ET)
Today's Range
Now: $2.22
50-Day Range
MA: $2.19
52-Week Range
Now: $2.22
Volume613,008 shs
Average Volume1.17 million shs
Market Capitalization$1.63 billion
P/E RatioN/A
Dividend YieldN/A
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NBRV



Sales & Book Value

Annual Sales$9.66 million
Book Value$0.10 per share


Net Income$-114,780,000.00
Net Margins-3,602.24%


Market Cap$1.63 billion
Next Earnings Date11/5/2019 (Estimated)

Receive NBRV News and Ratings via Email

Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.

Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics PLC - (NASDAQ:NBRV) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. The biotechnology company earned $0.53 million during the quarter, compared to analyst estimates of $0.88 million. Nabriva Therapeutics had a negative net margin of 3,602.24% and a negative return on equity of 139.52%. View Nabriva Therapeutics' Earnings History.

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Nabriva Therapeutics.

What price target have analysts set for NBRV?

7 brokers have issued 1-year price objectives for Nabriva Therapeutics' stock. Their predictions range from $2.00 to $13.00. On average, they anticipate Nabriva Therapeutics' stock price to reach $7.7143 in the next twelve months. This suggests a possible upside of 247.5% from the stock's current price. View Analyst Price Targets for Nabriva Therapeutics.

What is the consensus analysts' recommendation for Nabriva Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nabriva Therapeutics.

What are Wall Street analysts saying about Nabriva Therapeutics stock?

Here are some recent quotes from research analysts about Nabriva Therapeutics stock:
  • 1. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (8/23/2019)
  • 2. Northland Securities analysts commented, "We believe Xenleta is positioned to emerge as the 1st empiric monotherapy for treating CABP w/ potential global peak sales of $1B, supported by its significant clinical differentiation from existing therapies. Key Points Xenleta IV and Nabriva announced the FDA approval of Xenleta (lefamulin) IV and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) in adults. This represents the first approval of a new class antibiotic in nearly 2 decades. Xenleta is a semi-synthetic pleuromutilin that works via a unique mechanism of action by inhibiting the synthesis of bacteria protein necessary of proliferation." (8/16/2019)
  • 3. HC Wainwright analysts commented, "We employ a rNPV valuation model, driven by U.S. sales of: (1) lefamulin for CABP through 2028 (peak sales $460M); and (2) CONTEPO for cUTI through 2028 (peak sales $205M). We utilize a 15.0% discount rate for all cash flows, with zero terminal value after 2028, to arrive at our $7 price target (representing risk-adjusted per share values of about $6.50 for lefamulin and about $0.50 for CONTEPO). Risks to the attainment of our PT include failure to obtain FDA approval, unforeseen safety and/or tolerability issues, commercial sales trajectory meaningfully below then consensus expectations, and the dilution to current shareholders from additional equity offering(s)." (8/18/2019)

Has Nabriva Therapeutics been receiving favorable news coverage?

Media stories about NBRV stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Nabriva Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Nabriva Therapeutics.

Who are some of Nabriva Therapeutics' key competitors?

What other stocks do shareholders of Nabriva Therapeutics own?

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the folowing people:
  • Mr. Steven P. Gelone, Pres & COO (Age 51)
  • Dr. Colin Broom, Consultant & Director (Age 63)
  • Mr. Gary L. Sender, Chief Financial Officer (Age 57)
  • Mr. Theodore R. Schroeder, CEO & Director (Age 64)
  • Mr. Thomas Lembck, Chief Information Officer

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vivo Capital LLC (0.42%), Novo Holdings A S (0.36%), Renaissance Technologies LLC (0.13%), JPMorgan Chase & Co. (0.03%), Morgan Stanley (0.03%) and Wedbush Securities Inc. (0.01%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster, Steven P Gelone and Theodore R Schroeder. View Institutional Ownership Trends for Nabriva Therapeutics.

Which institutional investors are selling Nabriva Therapeutics stock?

NBRV stock was sold by a variety of institutional investors in the last quarter, including Novo Holdings A S, Vivo Capital LLC and Wedbush Securities Inc.. Company insiders that have sold Nabriva Therapeutics company stock in the last year include Colin Md Broom, Gary Sender and Steven P Gelone. View Insider Buying and Selling for Nabriva Therapeutics.

Which institutional investors are buying Nabriva Therapeutics stock?

NBRV stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, JPMorgan Chase & Co., Morgan Stanley, Wells Fargo & Company MN, A.R.T. Advisors LLC, Parametric Portfolio Associates LLC and Commonwealth Equity Services LLC. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster and Theodore R Schroeder. View Insider Buying and Selling for Nabriva Therapeutics.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $2.22.

How big of a company is Nabriva Therapeutics?

Nabriva Therapeutics has a market capitalization of $1.63 billion and generates $9.66 million in revenue each year. The biotechnology company earns $-114,780,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. View Additional Information About Nabriva Therapeutics.

What is Nabriva Therapeutics' official website?

The official website for Nabriva Therapeutics is

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN 1 L2, 19406. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected]

MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  565
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/24/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel